Business Context and Reporting Period
This Form 6-K filing by MediWound Ltd. reports the results of the 2025 Annual General Meeting of Shareholders held on May 15, 2025. The meeting addressed corporate governance matters, including director elections, auditor reappointment, executive compensation policies, and specific bonus approvals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on shareholder voting outcomes and corporate governance approvals rather than financial performance data.
Material Changes and Voting Results
Shareholders representing 42.6% of outstanding ordinary shares (4,598,651 shares) attended the meeting, establishing a quorum. All four proposals presented were approved:
- Director Re-election: All five nominees were re-elected. Support ranged from 91.1% for Stephen T. Wills to 99.7% for Dr. Vickie R. Driver and Shmuel (Milky) Rubinstein.
- Auditor Reappointment: Somekh Chaikin (a member firm of KPMG) was reappointed as the independent registered public accounting firm for the year ending December 31, 2025, with 99.8% approval.
- Compensation Policy: The renewal of the executive and director compensation policy for an additional three-year period was approved with 85.5% support. This also met the requisite special majority among non-controlling shareholders without a personal interest (85.3%).
- CEO Bonus: An annual cash bonus for CEO Ofer Gonen regarding 2024 performance was approved with 99.1% support, also meeting the requisite special majority (99.1%).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves as a procedural record of the shareholder meeting outcomes.
Investor Verification Checklist
- Verify the specific terms of the renewed three-year executive compensation policy referenced in Proposal 3.
- Confirm the exact amount of the 2024 annual cash bonus approved for CEO Ofer Gonen in Proposal 4.
- Review the full proxy statement (Exhibit 99.1 filed April 7, 2025) for detailed descriptions of the proposals and director biographies.
- Check subsequent filings for the 2024 audited financial results, as this 6-K does not contain financial performance data.